Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HRH2 | P25021 | 13/20 | 0.51 |
| ▸ | HRH1 | P35367 | 13/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139633 | 0.97 | KCNH2 (0.53) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL3598224 | 0.97 | KCNH2 (0.57) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4137801 | 0.95 | KCNH2 (0.59) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL1619409 | 0.94 | KCNH2 (0.54) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4134193 | 0.89 | KCNH2 (0.53) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4669237 | 0.88 | KCNH2 (0.52) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4134172 | 0.87 | KCNH2 (0.66) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL2967865 | 0.84 | KCNH2 (0.55) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4134400 | 0.84 | KCNH2 (0.67) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4128937 | 0.84 | KCNH2 (0.67) | KCNH2HRH2HRH1HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885HRH2 521/4885HRH1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.